文献速递浆细胞疾病

多发性骨髓瘤的治疗与疾病相关并发症:对生存者管理的启示

Treatment and disease-related complications in multiple myeloma: Implications for survivorship.
PubMed 文献 · Am J Hematol · 2020-03-13

多发性骨髓瘤已转变为慢性病,生存者管理需关注治疗与疾病相关并发症。本文综述了感染和第二肿瘤这两种最常见治疗相关死因的发生率、危险因素与管理,讨论了高危患者识别、个体化治疗选择及预防策略,并提出了改善骨髓瘤生存者医疗服务的生存者照护模式。

要点

  • 感染和第二肿瘤是多发性骨髓瘤最常见的两种治疗相关死因。
  • 识别高危毒性患者有助于个体化治疗选择和预防策略临床试验设计。
  • 体弱、持续肾功能不全及多线治疗难治患者需特别关注治疗毒性和生活质量。

核心结论

  • 多发性骨髓瘤已成为慢性病,优化治疗和疾病相关并发症的管理是生存者照护的关键组成部分。

研究设计与样本

  • 本文为综述,讨论骨髓瘤治疗和疾病相关并发症的发生率、危险因素和管理,并提出生存者照护模式。

主要发现

  • 感染和第二肿瘤是两种最常见的治疗相关死因,需要特别考虑。
  • 识别高危毒性患者有助于个体化治疗选择和针对这些患者的保护策略临床试验设计。
  • 体弱、持续肾功能不全和对多线治疗难治的患者需特别关注治疗毒性和生活质量。

关键数值与推荐

  • 预防性抗生素或免疫球蛋白替代可在高危患者中测试用于感染的一级预防。
  • 正在进行的试验的长期随访和流行病学数据将有助于识别如第二肿瘤等长潜伏期罕见毒性的性质和轨迹。

临床怎么用

  • 在骨髓瘤生存者照护中,应关注感染和第二肿瘤的预防与监测。
  • 根据患者毒性风险进行个体化治疗选择,并考虑在高危患者中测试预防性抗生素或免疫球蛋白替代。
  • 对体弱、持续肾功能不全和多线难治患者,需特别关注治疗毒性和生活质量。

局限性

  • 需长期随访正在进行的试验和流行病学数据以识别长潜伏期罕见毒性。
  • 针对高危患者保护策略的临床试验尚待开展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

New treatments have transformed multiple myeloma into a chronic disease. Hence, optimal management of treatment and disease-related complications remains a critical component of survivorship care. Survivorship care model in cancers requiring a fixed-duration therapy may not be applicable to myeloma, since patients are exposed to multiple lines of continuous therapy along the disease trajectory. The two most common therapy-related causes of death, which require special consideration, are infection and second cancers. Identifying patients at a high risk of toxicities will facilitate individualized treatment selection and designing clinical trials for protective strategies targeting those patients. For example, prophylactic antibiotic or immunoglobulin replacement can be tested for primary prevention of infections in high-risk patients. Long-term follow up of ongoing trials and epidemiologic data will help identify the nature and trajectory of rare toxicities with a long latency, such as secondary cancers. Patients who are frail, have persistent renal insufficiency, and refractory to multiple lines of therapy need special attention regarding treatment toxicity and quality of life. In this review, we discuss the incidence, risk-factors, and management of treatment and disease-related complications in myeloma, discuss knowledge gaps and research priorities in this area, and propose a survivorship care model to improve health-care delivery to a growing pool of myeloma survivors.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Chakraborty R, Majhail NS. Treatment and disease-related complications in multiple myeloma: Implications for survivorship. Am J Hematol. 2020. PMID: 32086970. doi:10.1002/ajh.25764

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。